References
- 1. Cushman M. (2007). Epidemiology and Risk Factors for Venous Thrombosis. Semin Hematol. 44(2), 62-9. DOI: 10.1053/j.seminhematol.2007.02.004.10.1053/j.seminhematol.2007.02.004
- 2. Tagalakis V, Patenaude V, Kahn SR, Suissa S. (2013). Incidence of and Mortality from Venous Thromboembolism in a Real-world Population: The Q-VTE Study Cohort. Am J Med. 126(9), 832.e13-21. DOI: 10.1016/j.amjmed.2013.02.024.10.1016/j.amjmed.2013.02.024
- 3. Goldhaber SZ. (2012). Venous thromboembolism: Epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 25(3), 235-42. DOI: 10.1016/j.beha.2012.06.007.10.1016/j.beha.2012.06.007
- 4. Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al. (2007). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 98(4), 756-64. DOI: 10.1160/TH07-03-0212.10.1160/TH07-03-0212
- 5. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. (2012). Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl), e278S-325S. DOI: 10.1378/chest.11-2404.10.1378/chest.11-2404
- 6. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. (2008). Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 133(6 Suppl), 381S-453S. DOI: 10.1378/chest.08-0656.
- 7. Falck-Ytter Y, Warwick D, Dahl OE, Fisher WD; International Surgical Thrombosis Forum. (2008). Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br. 90(2), 127-32. DOI: 10.1302/0301-620X.90B2.20106.10.1302/0301-620X.90B2.20106
- 8. Bass AR. (2015). Using new oral anticoagulants in patients undergoing major orthopedic surgery. Curr Rheumatol Rep. 17(4), 25. DOI: 10.1007/s11926-015-0498-z.
- 9. Eriksson BI, Quinlan DJ, Weitz JI. (2009). Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 48(1), 1-22. DOI: 10.2165/0003088-200948010-00001.10.2165/0003088-200948010-00001
- 10. Wong PC, Crain EJ, Pinto DJ, Watson CA. (2007). Dose-Dependent Antithrombotic Effects of Apixaban, an Oral Direct Factor Xa Inhibitor, in Prevention and Treatment of Thrombosis in Rabbit Models of Arteriovenous-Shunt and Venous Thrombosis at Doses That Preserve Hemostasis. Blood 110, 933.
- 11. Wong PC, Pinto DJ, Zhang D. (2011). Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 31(4), 478-92. DOI: 10.1007/s11239-011-0551-3.10.1007/s11239-011-0551-3
- 12. Imberti D, Gallerani M, Manfredini R. (2012). Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J Thromb Thrombolysis. 34(2), 208-13. DOI: 10.1007/s11239-012-0716-8.10.1007/s11239-012-0716-8
- 13. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. (2009). Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 361(6), 594–604. DOI: 10.1056/NEJMoa0810773.10.1056/NEJMoa0810773
- 14. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P and the ADVANCE-2 investigators. (2010). Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375, 807-15. DOI: 10.1016/S0140-6736(09)62125-5.10.1016/S0140-6736(09)62125-5
- 15. Lassen MR, Gallus A, Raskob G, Pineo G, Chen D, Ramirez LM. (2010). Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 363(26), 2487–98. DOI: 10.1056/NEJMoa1006885.10.1056/NEJMoa1006885
- 16. Huang J, Cao Y, Liao C, Wu L, Gao F. (2011). Apixaban versus enoxaparin in patients with total knee arthroplasty: a meta-analysis of randomized trials. Thromb Haemost. 105(2), 245-53. DOI: 10.1160/TH10-08-0552.10.1160/TH10-08-0552
- 17. Werth S, Halbritter K, Beyer-Westendorf J. (2012). Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. Ther Clin Risk Manag. 8, 139–47. DOI: 10.2147/TCRM.S24238.
- 18. Eriksson BI, Dahl OE, Buller HR, et al. (2005). A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. Thromb Haemost 3(1), 103–11. DOI: 10.1111/j.1538-7836.2004.01100.x.10.1111/j.1538-7836.2004.01100.x
- 19. Eriksson BI, Dahl OE, Huo MH, et al. (2011). Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 105(4), 721–9. DOI: 10.1160/TH10-10-0679.10.1160/TH10-10-0679
- 20. Wolowacz SE, Roskell NS, Plumb JM, Caprini JA, Eriksson BI. (2009). Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 101(1), 77–85. DOI: 10.1160/TH08-07-0493.10.1160/TH08-07-0493
- 21. Wurnig C, Clemens A, Rauscher H, Kleine E, Feuring M, Windhager R, Grohs J. (2015). Safety and efficacy of switching from low molecular weight heparin to dabigatran in patients undergoing elective total hip or knee replacement surgery. Thromb J. 13, 37. DOI: 10.1186/s12959-015-0066-9.10.1186/s12959-015-0066-9
- 22. Schulman S, Majeed A. (2012). The Oral Thrombin Inhibitor Dabigatran: Strengths and Weaknesses. Semin Thromb Hemost. 38(1), 7-15. DOI: 10.1055/s-0031-1300946.10.1055/s-0031-1300946
- 23. Mismetti P, Laporte S. (2008). Rivaroxaban: clinical pharmacology. Ann Fr Anesth Reanim. 27 (Suppl 27), S16–S21. DOI: 10.1016/S0750-7658(08)75142-6.10.1016/S0750-7658(08)75142-6
- 24. Steffel J, Luscher TF. (2009). Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown). 10(8), 616-23. DOI: 10.2459/JCM.0b013e32832edac0.
- 25. Eriksson BI, Borris LC, Friedman RJ, et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 358(26), 2765–75. DOI: 10.1056/NEJMoa0800374.10.1056/NEJMoa0800374
- 26. Kakkar AK, Brenner B, Dahl OE, et al. (2008). Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632), 31–9. DOI: 10.1016/S0140-6736(08)60880-6.10.1016/S0140-6736(08)60880-6
- 27. Lassen MR, Ageno W, Borris LC, et al. (2008). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 358(26), 2776–86. DOI: 10.1056/NEJMoa076016.10.1056/NEJMoa076016
- 28. Turpie AG, Lassen MR, Davidson BL, et al. (2009). Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet 373(9676), 1673–80. DOI: 10.1016/S0140-6736(09)60734-0.10.1016/S0140-6736(09)60734-0
- 29. Turpie AG, Haas S, Kreutz R, et al. (2014). A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 111(1), 94-102. DOI: 10.1160/TH13-08-0666.10.1160/TH13-08-0666
- 30. Anderson DR, Dunbar MJ, Bohm ER, et al. (2013). Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 158(11), 800–6. DOi: 10.7326/0003-4819-158-11-201306040-00004.10.7326/0003-4819-158-11-201306040-00004
- 31. Nutescu EA. (2013). Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. Expert Opin Pharmacother. 14(4), 525–34. DOI: 10.1517/14656566.2013.774374.10.1517/14656566.2013.774374
- 32. Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W. (2013). A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for postsurgical venous thromboembolism prevention. Postgrad Med. 125(4), 141-53. DOI: 10.3810/pgm.2013.07.2686.10.3810/pgm.2013.07.2686
- 33. Arrayas IG, Fernandez CS, Cerezo J G, Nicolás L B, Salas-Cansado M, Rubio-Terres C. (2012). Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement. Rev Esp Salud Publica. 86(6), 601-12. DOi: 10.4321/S1135-57272012000600006.10.4321/S1135-57272012000600006
- 34. NICE. (2012). Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance [TA245].
- 35. NICE. (2008). Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance [TA157].
- 36. Zindel S, Stock S, Müller D, Stollenwerk B. (2012). A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting. BMC Health Serv Res. 12, 192. DOI: 10.1186/1472-6963-12-192.10.1186/1472-6963-12-192
- 37. Ryttberg L, Diamantopoulos A, Forster F, Lees M, Fraschke A, Björholt I. (2011). Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. Expert Rev Pharmacoecon Outcomes Res. 11(5), 601-15. DOI: 10.1586/erp.11.65.10.1586/erp.11.65
- 38. Pravilnik o Listi lekova koji se propisuju i izdaju na teret sredstava obaveznog zdravstvenog osiguranja. Službeni glasnik RS 65/15; 71/15; 104/15, 24/16, 57/16, 61/16.
- 39. WHO Collaborating Centre for Drug Statistics Methodology. (2016). Guidelines for ATC classification and DDD assignment 2016. Oslo: World Health Organization.
- 40. Republički zavod za statistiku. Baza podataka. Retrieved Jun 01, 2016. from: http://webrzs.stat.gov.rs/WebSite/public/ReportView.aspx.